Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 30Gynecologic 13Thoracic 11Dermatologic 10Genitourinary 9Head & Neck 7Other solid neoplasm 6Breast 4Lymphoid 3CNS 3Sarcoma 2Other hematologic neoplasm 2NET 2Endocrine 2Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 3102Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Leukemia 2013Leukemia, Lymphocytic, Chronic, B-Cell 1771Myelodysplastic Syndromes 1298Hematologic Neoplasms 1067Lymphoma 1029Lymphoma, Non-Hodgkin 981Leukemia, Myelogenous, Chronic, BCR-ABL Positive 713Lymphoma, Follicular 704Lymphoma, Mantle-Cell 678Lymphoma, Large B-Cell, Diffuse 657Burkitt Lymphoma 642Multiple Myeloma 639Lymphoma, B-Cell, Marginal Zone 599Recurrence 587Hodgkin Disease 575Leukemia, Myelomonocytic, Chronic 495Lymphoma, Large-Cell, Immunoblastic 419Neoplasms 402Myeloproliferative Disorders 402Leukemia, Myeloid, Chronic-Phase 391Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 382Congenital Abnormalities 357Waldenstrom Macroglobulinemia 330Blast Crisis 324Leukemia, Myeloid, Accelerated Phase 290Lymphoma, T-Cell, Cutaneous 280Primary Myelofibrosis 270Anemia, Refractory, with Excess of Blasts 251

Interventions

Nivolumab 2Specimen Handling 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Turcot syndrome × Other hematologic neoplasm × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

NCT04439214 2021-04-06

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled 10 charts
LymphoidOther hematologic neoplasmPlasma cell

Turcot syndrome, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡